Mumbai, India – On February 15, a case using Shanghai MicroPort Medical (Group) Co., Ltd. ("MicroPort®") in-house developed Firehawk® Rapamycin Target Eluting Coronary Stent System ("Firehawk®") was successfully completed in H. J. Doshi Ghatkopar Hindu Sabha Hospital based in Mumbai, India, marking the first clinical use of Firehawk® in India and a milestone in MicroPort®'s market development in the country.
H. J. Doshi Ghatkopar Hindu Sabha Hospital is a cardiology hospital in Mumbai. The case was performed by Dr. Anil Potdar, Director of Interventional Cardiology of the hospital. Dr. Anil Potdar implanted a 2.5*18mm Firehawk® in the left circumflex artery of the patient. It is a tortuous and heavily calcified lesion. After balloon predilation, the stent successfully passed the lesion without malapposition. Dr. Anil Potdar was satisfied with the outcome and spoke highly of Firehawk®'s excellent crossability, trackability and pushability.
India has the third largest amount of PCI cases in the world, and the market has been experiencing rapid development in recent years. In the future, MicroPort® will further expand the India market to provide ideal medical solutions for local patients suffering from cardiovascular diseases.